Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 14/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005440 | 1.00 | MLYCD (0.35) | MLYCDGPBAR1ALDH1A1EPHX2RXRA | |
| SCHEMBL17013184 | 0.91 | MLYCD (0.35) | MLYCDGPBAR1ALDH1A1EPHX2HDAC4 | |
| SCHEMBL17005426 | 0.84 | MAPT (0.34) | ALDH1A1RXRARXRB | |
| SCHEMBL17005424 | 0.84 | MAPT (0.34) | ALDH1A1RXRARXRB | |
| SCHEMBL17005394 | 0.72 | MLYCD (0.43) | MLYCDGPBAR1RXRARXRBHDAC4 | |
| SCHEMBL15418036 | 0.69 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL15418035 | 0.69 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL3652937 | 0.67 | MLYCD (0.55) | MLYCDGPBAR1 | |
| SCHEMBL30016477 | 0.66 | MLYCD (0.48) | MLYCDGPBAR1ALDH1A1HDAC4 | |
| SCHEMBL15648032 | 0.66 | MLYCD (0.48) | MLYCDGPBAR1ALDH1A1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2933248-B1 | NOVEL RENIN INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2933248-A1 | NOVEL RENIN INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | REN, AGTR1, ACE | MLYCD 4230/4885GPBAR1 848/4885ALDH1A1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.